SOT Share Price Performance
د.م1,800.00
800.00 (80.00%)
117.9% overvalued intrinsic discount
د.م826.14
Fair Value
Price د.م1,800.00
Abdouahed د.م826.14
Fair Valueد.م826.14
Share Pricen/a
Société de Therapeutique Marocaine S.A. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 13 Fair Values set on narratives written by author
SOT Community Narratives
AB
Fair Value د.م826.14 117.9% overvalued intrinsic discount
Sothema has demonstrated robust growth through strategic product innovation and international expansion.
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Sothema has demonstrated robust growth through strategic product innovation and international expansion.
Considerations for the Next Five Years: Product Innovation and Expansion: Sothema's introduction of new products, particularly in priority therapeutic areas like diabetes and cardiology, demonstrates its commitment to innovation. The development of an injectable cartridge manufacturing line, expected to be operational by 2025, positions the company to produce advanced treatments, potentially enhancing its market share.Read more
9
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AB
د.م826.14
117.9% overvalued intrinsic discount
Abdouahed's Fair Value
Revenue
15.22% p.a.
Profit Margin
10.67%
Future PE
27.08x
Price in 2030
د.م2.14k
Trending Discussion
Recently Updated Narratives
AB
Sothema has demonstrated robust growth through strategic product innovation and international expansion.
Fair Value: د.م826.14 117.9% overvalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Société de Therapeutique Marocaine S.A. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- 44.59
- 47.35%
- 11.17%
- 27.1%
About SOT
- Founded
- 1976
- Employees
- 1219
- CEO
- WebsiteView website
Société de Therapeutique Marocaine S.A., a pharmaceutical company, engages in the manufacturing of licensed medicines in Morocco. It offers products in various therapeutic areas, such as allergology, oncology, cardiology, dental, dermatology, endocrinology, gastroenterology, gynecology, ophthalmology, ENT, pediatric, pulmonology, reanimation, rheumatology, central nervous system (CNS), and urology, as well as antibiotics and generics. The company also provides its products in various forms, including tablets, capsules, pouches, syrups, suspensions, powders, collyriums, flexible pouches, suppositories, creams and pomades, injectable solutions, and self-injectable syringes. In addition, it imports licensed medicines and dental products, as well as biotechnology products; and involved in subcontracted production. The company exports its products to Europe, Maghreb, Sub-Saharan Africa, and the Persian Gulf. Société de Therapeutique Marocaine S.A. was founded in 1976 and is based in Bouskoura, Morocco.